Literature DB >> 27849172

Novel E2 Glycoprotein Tetramer Detects Hepatitis C Virus-Specific Memory B Cells.

Maude Boisvert1, Wanrui Zhang2, Elizabeth J Elrod2, Nicole F Bernard3,4, Jean-Pierre Villeneuve1,5, Julie Bruneau1,6, Joseph Marcotrigiano7, Naglaa H Shoukry8,5, Arash Grakoui9,10.   

Abstract

Acute hepatitis C virus (HCV) infection culminates in viral persistence in the majority of cases. Abs that recognize the envelope glycoproteins E1 and E2 are generated during the late stages of acute infection, yet their contribution to spontaneous viral clearance remains controversial. Investigation of the humoral responses during acute HCV infection have been limited by the inability to directly identify and characterize HCV-specific B cells. In this study we describe the development of a novel tetramer of the E2 glycoprotein ectodomain (J6, genotype 2a strain), which allowed us to visualize E2-specific B cells longitudinally in the peripheral blood of HCV-infected individuals. HCV-specific class-switched memory B cells were detected in 3 out of 7 participants during late acute infection, with a mean frequency of 0.63% for positive samples (range 0.16-0.67%) and in 7 out of 7 participants with chronic infection with a mean frequency of 0.47% (range 0.20-0.78%). In a cross-sectional study, E2 tetramer positive population was detected in 28 out of 31 chronically infected individuals. Deep sequencing of the BCR from E2-specific class-switched memory B cells sorted from two independent participants revealed a focused repertoire suggestive of clonal selection. Tetramer-specific B cells exhibited skewed CDR3 length distribution and increased mutation frequency compared with naive B cells. This BCR profile is indicative of clonal expansion and affinity maturation. E2 tetramer allows for specific and sensitive ex vivo characterization of rare HCV-specific B cells in infected individuals, and will enable researchers to gain a better understanding of humoral immunity in HCV infection.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27849172      PMCID: PMC5136319          DOI: 10.4049/jimmunol.1600763

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Ex vivo characterization and isolation of rare memory B cells with antigen tetramers.

Authors:  Bettina Franz; Kenneth F May; Glenn Dranoff; Kai Wucherpfennig
Journal:  Blood       Date:  2011-05-06       Impact factor: 22.113

2.  Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.

Authors:  K G Hadlock; R E Lanford; S Perkins; J Rowe; Q Yang; S Levy; P Pileri; S Abrignani; S K Foung
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein.

Authors:  P Farci; A Shimoda; D Wong; T Cabezon; D De Gioannis; A Strazzera; Y Shimizu; M Shapiro; H J Alter; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

Review 4.  Dynamics of B cells in germinal centres.

Authors:  Nilushi S De Silva; Ulf Klein
Journal:  Nat Rev Immunol       Date:  2015-02-06       Impact factor: 53.106

5.  Intrahepatic B cell clonal expansions and extrahepatic manifestations of chronic HCV infection.

Authors:  Domenico Sansonno; Gianfranco Lauletta; Valli De Re; Felicia Anna Tucci; Pietro Gatti; Vito Racanelli; Mauro Boiocchi; Franco Dammacco
Journal:  Eur J Immunol       Date:  2004-01       Impact factor: 5.532

6.  Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.

Authors:  Muriel Lavie; Stéphane Sarrazin; Roland Montserret; Véronique Descamps; Thomas F Baumert; Gilles Duverlie; Karin Séron; François Penin; Jean Dubuisson
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

7.  Virus-Specific CD4+ T Cells Have Functional and Phenotypic Characteristics of Follicular T-Helper Cells in Patients With Acute and Chronic HCV Infections.

Authors:  Bijan Raziorrouh; Kathrin Sacher; Rajiv G Tawar; Florian Emmerich; Christoph Neumann-Haefelin; Thomas F Baumert; Robert Thimme; Tobias Boettler
Journal:  Gastroenterology       Date:  2015-11-14       Impact factor: 22.682

8.  Humoral immune response in acute hepatitis C virus infection.

Authors:  Dale M Netski; Tim Mosbruger; Erik Depla; Geert Maertens; Stuart C Ray; Robert G Hamilton; Stacy Roundtree; David L Thomas; Jane McKeating; Andrea Cox
Journal:  Clin Infect Dis       Date:  2005-07-22       Impact factor: 9.079

9.  A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans.

Authors:  John Lok Man Law; Chao Chen; Jason Wong; Darren Hockman; Deanna M Santer; Sharon E Frey; Robert B Belshe; Takaji Wakita; Jens Bukh; Christopher T Jones; Charles M Rice; Sergio Abrignani; D Lorne Tyrrell; Michael Houghton
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

10.  Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C.

Authors:  Jan M Pestka; Mirjam B Zeisel; Edith Bläser; Peter Schürmann; Birke Bartosch; Francois-Loïc Cosset; Arvind H Patel; Helga Meisel; Jens Baumert; Sergei Viazov; Kay Rispeter; Hubert E Blum; Michael Roggendorf; Thomas F Baumert
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-28       Impact factor: 11.205

View more
  10 in total

1.  Early T follicular helper cell activity accelerates hepatitis C virus-specific B cell expansion.

Authors:  Eduardo Salinas; Maude Boisvert; Amit A Upadhyay; Nathalie Bédard; Sydney A Nelson; Julie Bruneau; Cynthia A Derdeyn; Joseph Marcotrigiano; Matthew J Evans; Steven E Bosinger; Naglaa H Shoukry; Arash Grakoui
Journal:  J Clin Invest       Date:  2021-01-19       Impact factor: 14.808

2.  Annual Meeting of the Canadian Association for the Study of the Liver (CASL), the Canadian Network on Hepatitis C (CANHEPC) and the Canadian Association of Hepatology Nurses (CAHN) 2021 Abstracts.

Authors: 
Journal:  Can Liver J       Date:  2021-04-29

3.  Blockade of BAFF Reshapes the Hepatic B Cell Receptor Repertoire and Attenuates Autoantibody Production in Cholestatic Liver Disease.

Authors:  Manoj Thapa; Dana Tedesco; Sanjeev Gumber; Elizabeth J Elrod; Jin-Hwan Han; William H Kitchens; Joseph F Magliocca; Andrew B Adams; Arash Grakoui
Journal:  J Immunol       Date:  2020-04-24       Impact factor: 5.422

Review 4.  Immune system control of hepatitis C virus infection.

Authors:  Johnasha D Stuart; Eduardo Salinas; Arash Grakoui
Journal:  Curr Opin Virol       Date:  2020-11-01       Impact factor: 7.090

5.  Selective expansion of high functional avidity memory CD8 T cell clonotypes during hepatitis C virus reinfection and clearance.

Authors:  Mohamed S Abdel-Hakeem; Maude Boisvert; Julie Bruneau; Hugo Soudeyns; Naglaa H Shoukry
Journal:  PLoS Pathog       Date:  2017-02-01       Impact factor: 6.823

6.  Circulating CXCR3+ Tfh cells positively correlate with neutralizing antibody responses in HCV-infected patients.

Authors:  Jian Zhang; Wenpei Liu; Bo Wen; Ting Xie; Ping Tang; Yabin Hu; Liyan Huang; Kun Jin; Ping Zhang; Ziyan Liu; Ling Niu; Xiaowang Qu
Journal:  Sci Rep       Date:  2019-07-12       Impact factor: 4.379

7.  B cell overexpression of FCRL5 and PD-1 is associated with low antibody titers in HCV infection.

Authors:  Clinton O Ogega; Nicole E Skinner; Andrew I Flyak; Kaitlyn E Clark; Nathan L Board; Pamela J Bjorkman; James E Crowe; Andrea L Cox; Stuart C Ray; Justin R Bailey
Journal:  PLoS Pathog       Date:  2022-01-06       Impact factor: 6.823

8.  Serum neutralization activity declines but memory B cells persist after cure of chronic hepatitis C.

Authors:  Akira Nishio; Sharika Hasan; Heiyoung Park; Nana Park; Jordan H Salas; Eduardo Salinas; Lela Kardava; Paul Juneau; Nicole Frumento; Guido Massaccesi; Susan Moir; Justin R Bailey; Arash Grakoui; Marc G Ghany; Barbara Rehermann
Journal:  Nat Commun       Date:  2022-09-16       Impact factor: 17.694

Review 9.  Hepatitis C Vaccines, Antibodies, and T Cells.

Authors:  Naglaa H Shoukry
Journal:  Front Immunol       Date:  2018-06-28       Impact factor: 7.561

Review 10.  Towards a Systems Immunology Approach to Understanding Correlates of Protective Immunity against HCV.

Authors:  Naglaa H Shoukry
Journal:  Viruses       Date:  2021-09-18       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.